ASRS 2026: Ixo-vec gene therapy sustains reduced anti-VEGF burden at 5 years in wet AMD

Written on 07/21/2026

ASRS 2026: Ixo-vec gene therapy sustains reduced anti-VEGF burden at 5 years in wet AMD · A single injection with durable anti-VEGF expression · Five- ...

Read full article